Selective 5-HT2C Agonist for Weight Management
Solution Overview
Problem
Current obesity treatments are ineffective due to lack of efficacy or unacceptable side effects, and there is a need for a safe and effective method to manage weight by targeting the 5-HT2C receptor for reducing food intake and body weight.
Innovation Solution
The use of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, a selective 5-HT2C receptor agonist, for weight management, including weight loss and maintenance, by determining individual responsiveness and adjusting administration accordingly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current obesity treatments are used, then weight loss may be achieved, but unacceptable side effects occur
Solution Approach 1:
The patent changes the chemical parameter of the treatment by using (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, a selective 5-HT2C receptor agonist, instead of conventional obesity treatments. This specific chiral compound with particular molecular structure targets the 5-HT2C receptor to reduce food intake and body weight while avoiding the side effects associated with non-selective treatments
Solution Approach 2:
The patent introduces the 5-HT2C receptor as an intermediary target in the obesity treatment pathway. The selective agonist acts on this specific receptor to mediate the weight loss effect through appetite suppression and metabolic regulation, bypassing the harmful side effect pathways activated by conventional treatments
2Quantity of substance
If selective 5-HT2C receptor agonist is used, then weight loss is achieved with excellent tolerability, but individual responsiveness varies requiring administration adjustment
Solution Approach 1:
The patent implements dynamic administration strategies where the dosage and treatment regimen are adjusted based on individual patient responsiveness. The method allows for modification of administration parameters according to measured outcomes, creating a flexible and adaptive treatment approach that optimizes weight loss while maintaining excellent tolerability across different patient populations
Data Source
AI summary
Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual.